| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1191/0961203304lu2011oa IVIG in APS pregnancySezione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy, triolog{at}tiscalinet.it
Sezione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy
Sezione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy
Sezione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy
Sezione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy
Dipartimento di Ostetricia e Ginecologia, University of Palermo, Palermo, Italy
Dipartimento di Ostetricia e Ginecologia, University of Palermo, Palermo, Italy
Sezione di Medicina Interna, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy For more than two decades, the intravenous administration of high doses of IgG pooled from the plasma of healthy donors (immune globulin therapy, also known as IVIG) has benefited patients with a variety of autoimmune disorders. A potential therapeutic role of IVIG in the prevention of thrombosis and of miscarriages in antiphospholipid syndrome (APS) has been postulated. Multicenter randomized controlled trials attempted to define the role of IVIG in preventing pregnancy complications in APS indicate that simple anticoagulation could not be completely satisfactory, and certain patient subgroups might take advantage of IVIG therapy alone or in combination with heparin.
Key Words: APS IVIG pregnancy recurrent fetal loss
This article has been cited by other articles:
|
||||||||||||||||||||||||

